1379445-77-8

Upstream product

• 5292-43-3 bromoacetic acid tert-butyl ester 
• 93-91-4 1-phenylbutan-1,3-dione 

Downstream Products

• 1379445-54-1 {5-methyl-1-[2-(morpholin-4-ylsulfonyl)benzyl]-3-phenyl-1H-pyrazol-4-yl}acetic acid 
• 1379445-61-0 {5-methyl-3-phenyl-1-[2-(piperidin-1-ylsulfonyl)benzyl]-1H-pyrazol-4-yl}acetic acid 
• 1379445-62-1 {1-[4-fluoro-2-(piperazin-1-ylsulfonyl)benzyl]-5-methyl-3-phenyl-1H-pyrazol-4-yl}acetic acid 
• 1322082-29-0 tert-Butyl (5-methyl-3-phenyl-1H-pyrazol-4-yl)acetate 
• 1379445-86-9 tert-Butyl {5-methyl-3-phenyl-1-[2-(phenylsulfonyl)benzyl]-1H-pyrazol-4-yl}-acetate 
• 1379445-90-5 tert-Butyl (5-methyl-3-phenyl-1-{2-[(phenylsulfonyl)methyl]benzyl}-1H-pyrazol-4-yl)acetate 
• 1379445-96-1 tert-butyl [1-(2-benzylbenzyl)-5-methyl-3-phenyl-1H-pyrazol-4-yl]acetate 
• 1379446-02-2 tert-Butyl [1-(2-benzoyl benzyl)-5-methyl-3-phenyl-1H-pyrazol-4-yl]acetate 
• 1379445-89-2 tert-Butyl [1-(biphenyl-2-ylmethyl)-5-methyl-3-phenyl-1H-pyrazol-4-yl]acetate 
• 1379445-94-9 tert-Butyl [5-methyl-1-(2-phenoxybenzyl)-3-phenyl-1H-pyrazol-4-yl]acetate 
• 1379445-95-0 tert-Butyl {5-methyl-1-[2-(morpholin-4-ylsulfonyl)benzyl]-3-phenyl-1H-pyrazol-4-yl}acetate 
• 1379445-58-5 (1-{2-[(dimethylamino)sulfonyl]benzyl}-5-methyl-3-phenyl-1H-pyrazol-4-yl)acetic acid 
• 1379446-05-5 tert-Butyl {5-methyl-3-phenyl-1-[2-(piperidin-1-ylsulfonyl)benzyl]-1H-pyrazol-4-yl}acetate 
• 1379446-01-1 tert-Butyl (1-{2-[(dimethylamino)sulfonyl]benzyl}-5-methyl-3-phenyl-1H-pyrazol-4-yl)acetate 

Relevant academic research and scientific papers

Naturally occurring bioactive 5-ethylidenehydantoins as inspiration for the development of analogues

Many naturally occurring 5-ethylidenehydantoins and their derivatives exhibit extensive biological activities; this characteristic has inspired us to prepare analogues. Fourteen such analogues with the core structure of 5-ethylidenehydantoin were synthesi

2-(1H-Pyrazol-4-yl)acetic acids as CRTh2 antagonists

High throughput screening identified the pyrazole-4-acetic acid substructure as CRTh2 receptor antagonists. Optimisation of the compounds uncovered a tight SAR but also identified some low nanomolar inhibitors.

NEW PYRAZOLE DERIVATIVES HAVING CRTH2 ANTAGONISTIC BEHAVIOUR

The present invention relates to a compound of formula (I), to the process for preparing such compounds and to their use in the treatment of a pathological condition or disease susceptible to amelioration by CRTh2 antagonist activity.

New pyrazole derivatives having CRTh2 antagonistic behaviour

The present invention relates to a compound of formula (I), to the process for preparing such compounds and to their use in the treatment of a pathological condition or disease susceptible to amelioration by CRTh2 antagonist activity.